Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
LINC00968
Specific or universal ncRNAs
Specific ncRNAs
Class
Long noncoding RNA
Biomarker
Yes
Biomarker application
Treatment
Upstream regulatory factors
Not available
Downstream target
WNT2/Ī²-catenin signaling pathway
Cancer name
Breast Cancer
Cancer site
Breast
Treatment type
Chemotherapy
Drug
Adriamycin/Paclitaxel/Vincristine
Impact of wild-type ncRNA on chemotherapy resistance
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
Down
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
Overexpressed LINC00968 contributes to reduced drug resistance in breast cancer cells by inhibiting the activation of the Wnt2/Ī²-catenin signaling pathway through silencing WNT2.
Tissue resource
breast cancer tissues and adjacent normal tissues
breast cancer doxorubicin drug-resistant cell lines MCF-7/ADM
breast cancer doxorubicin drug-resistant cell lines KPL-4/ADM
human embryonic kidney cell lines HEK-293T
Experiment
qRT-PCR,Western blot,Northern blot,Dual-luciferase reporter assay
Institute
China-Japan Union Hospital of Jilin University
American Type Culture Collection
Country
China
USA
Continent
Asia
North American
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.